SG11202005920PA - Compositions comprising lipid-based nanoparticles for treating diabetes mellitus - Google Patents

Compositions comprising lipid-based nanoparticles for treating diabetes mellitus

Info

Publication number
SG11202005920PA
SG11202005920PA SG11202005920PA SG11202005920PA SG11202005920PA SG 11202005920P A SG11202005920P A SG 11202005920PA SG 11202005920P A SG11202005920P A SG 11202005920PA SG 11202005920P A SG11202005920P A SG 11202005920PA SG 11202005920P A SG11202005920P A SG 11202005920PA
Authority
SG
Singapore
Prior art keywords
lipid
compositions
diabetes mellitus
treating diabetes
based nanoparticles
Prior art date
Application number
SG11202005920PA
Other languages
English (en)
Inventor
W Blair Geho
Original Assignee
Sdg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sdg Inc filed Critical Sdg Inc
Publication of SG11202005920PA publication Critical patent/SG11202005920PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202005920PA 2018-01-05 2019-01-07 Compositions comprising lipid-based nanoparticles for treating diabetes mellitus SG11202005920PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862614109P 2018-01-05 2018-01-05
PCT/US2019/012557 WO2019136386A1 (en) 2018-01-05 2019-01-07 Compositions comprising lipid-based nanoparticles for treating diabetes mellitus

Publications (1)

Publication Number Publication Date
SG11202005920PA true SG11202005920PA (en) 2020-07-29

Family

ID=67143976

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005920PA SG11202005920PA (en) 2018-01-05 2019-01-07 Compositions comprising lipid-based nanoparticles for treating diabetes mellitus

Country Status (11)

Country Link
US (2) US20200375913A1 (ko)
EP (1) EP3735232A4 (ko)
JP (1) JP2021509900A (ko)
KR (1) KR20200106912A (ko)
CN (1) CN111712236A (ko)
AU (1) AU2019205795A1 (ko)
BR (1) BR112020013460A2 (ko)
CA (1) CA3086771A1 (ko)
MX (1) MX2020007067A (ko)
SG (1) SG11202005920PA (ko)
WO (1) WO2019136386A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US20210137838A1 (en) 2017-03-13 2021-05-13 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
AU2020271901A1 (en) 2019-04-12 2021-11-04 Sdg, Inc. Lipid-based nanoparticles and use of same in optimized insulin dosing regimens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610758A4 (en) * 2003-03-19 2011-11-02 Harry Hebblewhite METHOD AND SYSTEM FOR DETERMINING INSULIN DOSAGE PLANES AND CARBOHYDRATE / INSULIN RELATIONSHIPS IN DIABETICS
WO2004084820A2 (en) * 2003-03-19 2004-10-07 Harry Hebblewhite Method and system for determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients
US20110135725A1 (en) * 2005-05-23 2011-06-09 Sdg, Inc. Lipid Construct for Delivery of Insulin to a Mammal
KR101389226B1 (ko) * 2005-05-23 2014-04-25 에스디지,인코포레이티드 포유동물에게 인슐린을 전달하기 위한 지질 구조물
US8962015B2 (en) * 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US20120035105A1 (en) * 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
EP2683410A2 (en) * 2011-03-08 2014-01-15 Access Pharmaceuticals, Inc. Targeted nanocarrier systems for delivery of actives across biological membranes
US20180000953A1 (en) * 2015-01-21 2018-01-04 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
US20210137838A1 (en) * 2017-03-13 2021-05-13 Sdg, Inc. Lipid-based nanoparticles with enhanced stability

Also Published As

Publication number Publication date
US20240108585A1 (en) 2024-04-04
CN111712236A (zh) 2020-09-25
KR20200106912A (ko) 2020-09-15
BR112020013460A2 (pt) 2020-12-01
US20200375913A1 (en) 2020-12-03
WO2019136386A1 (en) 2019-07-11
MX2020007067A (es) 2020-09-09
CA3086771A1 (en) 2019-07-11
EP3735232A1 (en) 2020-11-11
EP3735232A4 (en) 2021-09-08
JP2021509900A (ja) 2021-04-08
AU2019205795A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
HK1253915A1 (zh) 表面改性用組合物
IL259123B (en) The compositions for applying to the skin
SG11202005920PA (en) Compositions comprising lipid-based nanoparticles for treating diabetes mellitus
GB201715639D0 (en) Compositions for wound treatment
EP3263132A4 (en) Composition for treating il-6-related diseases
HK1258445A1 (zh) 表面修飾用功能性組合物
EP3252129A4 (en) Composition for removing sulfur-containing compounds
EP3705545A4 (en) SURFACE TREATMENT COMPOSITION
EP3638228C0 (en) COMPOUNDS FOR TREATING TRIPLE NEGATIVE BREAST CANCER
EP3569238A4 (en) COMPOSITION FOR TREATING NEWBORN EHI
EP3609528A4 (en) COMPOSITIONS FOR THE TREATMENT OF ADDICTION
EP3274053A4 (en) Tolerogenic nanoparticles for treating diabetes mellitus
PT3273947T (pt) Composição para a saúde ocular
PL3603686T3 (pl) Kompozycja wypełniacza do leczenia lipoatrofii
EP3288636A4 (en) COMPOSITIONS FOR THE TREATMENT OF EPISTAXIS
EP3555360A4 (en) COMPOSITION FOR TREATMENT OF FABRICS
IL261774B (en) Compositions for treating dermatological conditions
EP3489280A4 (en) SURFACE TREATMENT AGENT FOR THERMAL CONDUCTING POLYORGANOSILOXANE COMPOSITION
SG11202008959RA (en) Composition for improving skin conditions
PT3574912T (pt) Composição para tratamento de doença diabética
EP3632421A4 (en) COMPOSITION FOR IMPROVING BRAIN FUNCTION
EP3369419A4 (en) Composition for treating diabetes
EP3013958A4 (en) Glucan-encapsulated sirna for treating type 2 diabetes mellitus
PL3692130T3 (pl) Kompozycja obejmująca prekursor składników lotnych
ZA201800974B (en) Combination composition comprising fgf-18 compound